PARIS, Aug 3 (Reuters) – French drugmaker Sanofi (SASY.PA) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (TBIO.O), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
“Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics,” Chief Executive Paul Hudson said.Reporting by Matthias Blamont and Sudip Kar-Gupta; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles.
FIA President Mohammed Ben Sulayem hails new agreement as a vital step forward for racing…
Indonesia’s rapidly expanding investor community is creating a new opportunity for financial technology companies: connecting…
Nevada’s emergence as a life sciences destination is gaining momentum, and Roseman Bioventures is positioning…
Hyperion Materials & Technologies is working with CADDi to centralise engineering data and accelerate quotation…
Launching a business in Ontario is an exciting but strategic endeavour that begins with a…
The next stage of premium consumer electronics is increasingly about ecosystems rather than individual devices.…